




I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231 on October 18, 2001.


Doran R. Pace, Patent Attorney

151
PRELIMINARY AMENDMENT
Examining Group 1646
Patent Application
Docket No. UF-243X
Serial No. 09/648,864

RECEIVED

JAN 04 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Janet Andres, Ph.D.
Art Unit : 1646
Applicants : Howard M. Johnson, Mustafa G. Mujtaba
Serial No. : 09/648,864
Filed : August 25, 2000
For : Materials and Methods for Inhibition of IgE Production

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Applicants respectfully request that the above-identified patent application be amended as follows:

In the Specification

Please substitute the following paragraph on page 1, beginning at line 19:

IFN α 's have been shown to inhibit various types of cellular proliferation. IFN α 's are especially useful against hematologic malignancies such as hairy-cell leukemia (Quesada *et al.*, 1984). Further, these proteins have also shown activity against multiple myeloma, chronic lymphocytic leukemia, low-grade lymphoma, Kaposi's sarcoma, chronic myelogenous leukemia, renal-cell carcinoma, urinary bladder tumors and ovarian cancers (Bonnem *et al.*, 1984; Oldham, 1985). The role of interferons and interferon receptors in the pathogenesis of certain autoimmune and inflammatory diseases has also been investigated (Benoit *et al.*, 1993).